Immunotherapy Treatment for Triple Negative Breast Cancer
Berger ER, Park T, Saridakis A, Golshan M, Greenup RA, Ahuja N. Immunotherapy Treatment for Triple Negative Breast Cancer. Pharmaceuticals 2021, 14: 763. PMID: 34451860, PMCID: PMC8401402, DOI: 10.3390/ph14080763.Peer-Reviewed Original ResearchTriple-negative breast cancerImmune related adverse eventsBreast cancerMetastatic settingMetastatic triple-negative breast cancerEarly breast cancer settingImmune checkpoint inhibitor therapyBreast cancer settingCheckpoint inhibitor therapyRelated adverse eventsLocal recurrence rateHigh-risk subtypesNegative breast cancerDevelopment of biomarkersTypes of cancerImmunotherapy useAdverse eventsCheckpoint therapyOverall survivalStandard therapySystemic treatmentInhibitor therapyDismal prognosisImmunotherapy treatmentRecurrence rate